Cytomegalovirus-specific T-cell immunity to assign the infection status in individuals with passive immunity: A proof of principle

Journal of Clinical Virology

Volumn 54, Issue 3, 2012, Pages 272-275

  Schmidt, Tina ^a   Ritter, Marion ^a   Dirks, Jan ^a   Gärtner, Barbara C ^a   Sester, Urban ^a   Sester, Martina ^a  

^a SAARLAND UNIVERSITY   (Germany)

Author keywords

Antibody; Cellular immunity; Cytomegalovirus; Passive immunity; Transfusion; Transplantation

Indexed keywords

BASILIXIMAB; IMMUNOGLOBULIN G; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RITUXIMAB; TACROLIMUS;

ADULT; ANTIBODY TITER; ARTICLE; BLOOD GROUP ABO INCOMPATIBILITY; CASE REPORT; CD4+ T LYMPHOCYTE; CELLULAR IMMUNITY; CYTOMEGALOVIRUS INFECTION; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMAN; HUMORAL IMMUNITY; IMMUNOSUPPRESSIVE TREATMENT; LIMIT OF DETECTION; MALE; PASSIVE IMMUNIZATION; PRIORITY JOURNAL;

ADULT; ANTIBODIES, VIRAL; CYTOKINES; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HUMANS; MALE; MIDDLE AGED; T-LYMPHOCYTES; TRANSPLANTATION, HOMOLOGOUS;

EID: 84861680292     PISSN: 13866532     EISSN: 18735967     Source Type: Journal    
DOI: 10.1016/j.jcv.2012.03.001     Document Type: Article

References (9)

1. Kotton C.N., Kumar D., Caliendo A.M., Asberg A., Chou S., Snydman D.R., et al. International consensus guidelines on the management of cytomegalovirus in solid organ transplantation. Transplantation 2010, 89:779-795.
2. Sester M., Gärtner B.C., Sester U., Girndt M., Mueller-Lantzsch N., Köhler H. Is the CMV serologic status always accurate?A comparative analysis of humoral and cellular immunity. Transplantation 2003, 76:1229-1231.
3. Sester U., Presser D., Dirks J., Gärtner B.C., Köhler H., Sester M. PD-1 expression and IL-2 loss of cytomegalovirus-specific T cells correlates with viremia and reversible functional anergy. Am J Transplant 2008, 8:1486-1497.
4. Couzi L., Helou S., Bachelet T., Moreau K., Martin S., Morel D., et al. High incidence of anticytomegalovirus drug resistance among D+R- kidney transplant recipients receiving preemptive therapy. Am J Transplant 2012, 12:202-209.
5. Triulzi D.J. Specialized transfusion support for solid organ transplantation. Curr Opin Hematol 2002, 9:527-532.
6. Preiksaitis J.K., Sandhu J., Strautman M. The risk of transfusion-acquired CMV infection in seronegative solid-organ transplant recipients receiving non-WBC-reduced blood components not screened for CMV antibody (1984 to 1996): experience at a single Canadian center. Transfusion 2002, 42:396-402.
7. Crough T., Khanna R. Immunobiology of human cytomegalovirus: from bench to bedside. Clin Microbiol Rev 2009, 22:76-98.
8. Sester M., Gärtner B.C., Sester U. Monitoring of CMV specific T-cell levels after organ transplantation. J Lab Med 2008, 32:121-130.
9. Sester M., Sester U., Gärtner B., Heine G., Girndt M., Mueller-Lantzsch N., et al. Levels of virus-specific CD4 T cells correlate with cytomegalovirus control and predict virus-induced disease after renal transplantation. Transplantation 2001, 71:1287-1294.